Investors

Company Profile

Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:

Stock Quote

Price

Change

High

View Details Stock Lookup

Date	Title and Summary
Toggle Summary 26 Feb '20	Arena Announces Management and Program Updates and Reports Fourth Quarter and Full-Year 2019 Financial Results - Appoints Kevin R. Lind as President and Chief Executive Officer of Arena Neuroscience, Inc. - Appoints Laurie D. Stelzer as Executive Vice President and Chief Financial Officer of Arena - Expects to deliver up to eight major data readouts between 2020-21 and multiple INDs - Progressing first- or Earnings
Toggle Summary 21 Feb '20	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , Feb. 21, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 10, 2020 the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 132,100 shares of its common stock to 20 new employees. General

Date

Title and Summary

Feb '20

Arena Announces Management and Program Updates and Reports Fourth Quarter and Full-Year 2019 Financial Results

- Appoints Kevin R. Lind as President and Chief Executive Officer of Arena Neuroscience, Inc. - Appoints Laurie D. Stelzer as Executive Vice President and Chief Financial Officer of Arena - Expects to deliver up to eight major data readouts between 2020-21 and multiple INDs - Progressing first- or

Earnings

Feb '20

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , Feb. 21, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 10, 2020 the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 132,100 shares of its common stock to 20 new employees.

General